Over the last few years I’ve worked with pharma marketers trying to preach and teach the virtues of digital channels. It has been a thankless task, with bucket loads of blood, sweat, and tears of frustration.
Over the last few years I’ve worked with pharma marketers trying to preach and teach the virtues of digital channels. It has been a thankless task, with bucket loads of blood, sweat, and tears of frustration. I have used a number of different techniques, from talking about the revolution in big forums to small softly, softly‚ “express yourself” type workshops (without incense sticks or trickling water).
Once the adrenalin rush dies down I try to analyze what impact this may have had.
To be fair, some glacially slow progress has been made as the median knowledge of the industry inches forward, but it has not been the tidal wave that some had predicted, or hoped for.
Should we be surprised? Probably not.
Looking back to my earlier days as an eBusiness evangelist in the late 90s, where a solid part of our strategic recommendations included “give your employees access to email”, we spent many a night conjuring projections with terms such as “dis-intermediation” and the like.
I recently took a fresh look at some of those crazy visionary presentations, and guess what: many of them were right, but nearly all the timelines were wrong.
So what went wrong then, and is the same thing happening now?
Nothing actually went wrong, it’s just that we all got a bit carried away with the media buzz out there, and forget that the majority of world is shackled with resistance to change. Some of that change is personal, some of it is organizational, some legal etc. It simply takes a long time for these to all be aligned for things to happen.
But if you peer through the mist today you can see that there is progress, and that there is no going back. To believe that the current models will not change is simply not accepting the evidence that confronts the observer, taken the avalanche of factors currently impacting our industry.
So if we all agree that the current model is broken, and that we need to be moving somewhere else why is progress still so slow?
There are many market research papers out there identifying the blocking factors to the adoption of digital tools as part of a multi-channel approach. Here are the usual culprits:
It is all of the above, but perhaps we’ve not looked at this through the right prism.
Senior management is there to make educated decisions based on the evidence at hand. They are tasked to steer the ship safely, based on limited information and gut feeling built on decades of experience.
If we are honest with our selves, we have been pretty weak at building the case for doing some of the stuff that we’re asking our stakeholders to adopt. Yes, in individual impact studies we can demonstrate that an eDetail, or a self-directed video, has a greater impact than none, but we’re only looking at part of the equation in an artificial configuration, and not even attempting to truly understand the influence and behavioral change attributed to the information coming from different channels.
To build traction and credibility we need to develop and demonstrate deep understanding of channel impact and attribution (including the sales force).
We need to harness this as a lifestyle, living and breathing multiple channels. Knowing what each channel can bring to the table, within the specific environment of each ‘business case’ and how to mix effectively a selected number of them in a congruent manner.
The title of this post is “Why won’t those damn marketers ‘do’ digital?”
Now that you’ve read this far I would postulate a different, and more appropriate cut on this:
Stop pushing the virtues of digital. If you can demonstrate that channel X and Y , used together, will drive the best business and customer outcomes, your marketers will sit up, listen, then beg to know more! Push will become pull, and the marketers will finally skill themselves up with the tools of tomorrow.
In conclusion, we need to become masters of channel selection, capable of building quantified scenarios based on desired outcomes and limited resources. And yes, that will take real investment, but senior management should acknowledge and invest accordingly.
Sven Awege runs the Pharma Strategic blog.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.